L1PA Stock Overview
An investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Lee's Pharmaceutical Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.14 |
| 52 Week High | HK$0.18 |
| 52 Week Low | HK$0.12 |
| Beta | 0.87 |
| 11 Month Change | 3.62% |
| 3 Month Change | 12.60% |
| 1 Year Change | -4.03% |
| 33 Year Change | -62.17% |
| 5 Year Change | n/a |
| Change since IPO | -72.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| L1PA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.4% | -5.0% | -1.3% |
| 1Y | -4.0% | -22.0% | 7.4% |
Return vs Industry: L1PA exceeded the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: L1PA underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| L1PA volatility | |
|---|---|
| L1PA Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: L1PA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: L1PA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 993 | n/a | www.leespharm.com |
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. It focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments.
Lee's Pharmaceutical Holdings Limited Fundamentals Summary
| L1PA fundamental statistics | |
|---|---|
| Market cap | €88.78m |
| Earnings (TTM) | €7.73m |
| Revenue (TTM) | €146.98m |
11.5x
P/E Ratio0.6x
P/S RatioIs L1PA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L1PA income statement (TTM) | |
|---|---|
| Revenue | HK$1.20b |
| Cost of Revenue | HK$581.63m |
| Gross Profit | HK$617.44m |
| Other Expenses | HK$554.38m |
| Earnings | HK$63.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 51.49% |
| Net Profit Margin | 5.26% |
| Debt/Equity Ratio | 14.2% |
How did L1PA perform over the long term?
See historical performance and comparison